Pierre Vandepapeliere

Summary

Affiliation: GlaxoSmithKline Biologicals
Country: Belgium

Publications

  1. ncbi Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
    Vaccine 25:8585-97. 2007
  2. ncbi Therapeutic vaccination against chronic viral infections
    Pierre Vandepapeliere
    Clinical R and D HIV vaccines and anti infective therapeutic vaccines, GlaxoSmithKline Biologicals, Rue de l Institut 89, B 1330, Rixensart, Belgium
    Lancet Infect Dis 2:353-67. 2002
  3. ncbi Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 89 Rue de 1 institut, B 1330 Rixensart, Belgium
    Vaccine 23:2591-601. 2005
  4. ncbi Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Infect Dis 192:2099-107. 2005
  5. doi Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 89 Rue de l Institut, 1330 Rixensart, Belgium
    Vaccine 26:1375-86. 2008

Detail Information

Publications5

  1. ncbi Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
    Vaccine 25:8585-97. 2007
    ....
  2. ncbi Therapeutic vaccination against chronic viral infections
    Pierre Vandepapeliere
    Clinical R and D HIV vaccines and anti infective therapeutic vaccines, GlaxoSmithKline Biologicals, Rue de l Institut 89, B 1330, Rixensart, Belgium
    Lancet Infect Dis 2:353-67. 2002
    ..However, with a better understanding of the immunological mechanisms involved in the control of disease successful therapeutic vaccines, used alone or in combination with other therapies, are an achievable goal...
  3. ncbi Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 89 Rue de 1 institut, B 1330 Rixensart, Belgium
    Vaccine 23:2591-601. 2005
    ..AS02A can be considered as a useful adjuvant that strongly enhances the cellular and humoral responses of subunit protein vaccines...
  4. ncbi Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Infect Dis 192:2099-107. 2005
    ..A therapeutic vaccine composed of HPV-6 L2E7 fusion protein and AS02A adjuvant was evaluated in conjunction with conventional therapies in subjects with anogenital warts...
  5. doi Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 89 Rue de l Institut, 1330 Rixensart, Belgium
    Vaccine 26:1375-86. 2008
    ..g. malaria, HIV infection and tuberculosis, and for special target populations such as subjects with an impaired immune response, due to age or medical conditions...